Raymond James analyst John Ransom maintains CVS Health (NYSE:CVS) with a Outperform and lowers the price target from $110 to $90.
Raymond James lowered CVS Health (NYSE:CVS) price target from $110 to $90 Read Post »
RBC Capital analyst Ben Hendrix reiterates CVS Health (NYSE:CVS) with a Outperform and maintains $102 price target.
RBC Capital maintained CVS Health (NYSE:CVS) $102 price target Read Post »
Piper Sandler analyst Jessica Tassan initiates coverage on CVS Health (NYSE:CVS) with a Overweight rating and announces Price Target of $85.
Piper Sandler announced CVS Health (NYSE:CVS) Price Target of $85 Read Post »
Bank of America Securities analyst Michael Cherny maintains CVS Health (NYSE:CVS) with a Buy and lowers the price target from $111 to $104.
Bank of America lowered CVS Health (NYSE:CVS) price target from $111 to $104 Read Post »
CVS Health (NYSE:CVS) Keeps Quarterly Dividend at $0.605 a Share, Payable May 1 to Holders of Record April 21
CVS Health (NYSE:CVS) Keeps Quarterly Dividend at $0.605 a Share Read Post »
Raymond James analyst John Ransom lowered its price target on CVS Health (NYSE:CVS) to $110 from $115 and maintained the stock’s “outperform” rating. The analyst told investors in a research note that CVS Health’s fourth-quarter results were in line with their pre-announcement, that guidance for 2023 remained unchanged, and that the company announced the acquisition of Oak Street Health, a health firm on Oak Street.
Raymond James: Lowered CVS Health (NYSE:CVS) price target to $110 from $115 Outperform Read Post »
CVS Health (NYSE:CVS) issued an update on its FY23 earnings guidance. The company provided earnings per share guidance of $8.70 to $8.90 for the period, compared to the consensus earnings per share estimate of $8.86.
CVS Health (NYSE:CVS) Updates FY23 Earnings Guidance Read Post »
RBC Capital Reiterates Outperform on CVS Health(NYSE:CVS), Maintains $115 Price Target.
RBC Capital Reiterates Outperform on CVS Health(NYSE:CVS), Maintains $115 Price Target Read Post »
Barclays Adjusts Price Target on CVS Health to $110 From $118, Maintains Overweight Rating.
Barclays Adjusts Price Target on CVS Health (NYSE:CVS) to $110 From $118 Read Post »
CVS Health (NYSE:CVS)’s stock had its “outperform” rating reissued by stock analysts at Royal Bank of Canada. Its target price is $115.00.
CVS Health (NYSE:CVS) Stock Rating Reaffirmed by Royal Bank of Canada Read Post »
DA Davidson Adjusts CVS Health’s (NYSE:CVS) Price Target to $106 From $115, Maintains Buy Rating.
DA Davidson Adjusts CVS Health’s (NYSE:CVS) Price Target to $106 From $115 Read Post »
February 8, 2023 – CVS Health Corporation (NYSE: CVS) today announced operating results for the three months and year ended December 31, 2022. Q4 adjusted earnings Wednesday of $1.99 per diluted share,Analysts polled by Capital IQ expected $1.93. Revenue for the quarter ended Dec. 31 was $83.8 billion, Analysts surveyed by Capital IQ expected $76.4 billion. The company said it expects full-year 2023 adjusted earnings of $8.70 to $8.90 per diluted share. Analysts polled by Capital IQ expect $8.86. FOURTH QUARTER HIGHLIGHTS： Total revenues increased to $83.8 billion, up 9.5% compared to prior year. GAAP diluted EPS of $1.75 and Adjusted EPS of $1.99. Announced a 10% increase to the quarterly shareholder dividend, which became effective with the February 1, 2023 dividend distribution. Returned $2.9 billion to shareholders through dividends, while repurchasing 34.1 million shares of common stock and authorizing a new $10.0 billion share repurchase program. Increased unique digital customers by seven million
CVS Health (NYSE:CVS) Total revenues increased to $83.8 billion, up 9.5% YoY in Q4 2022 Read Post »